{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T13:34:27Z","timestamp":1793885667675,"version":"4.8.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2020,4,13]],"date-time":"2020-04-13T00:00:00Z","timestamp":1586736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,4,13]],"date-time":"2020-04-13T00:00:00Z","timestamp":1586736000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1245\/s10434-020-08324-w","type":"journal-article","created":{"date-parts":[[2020,4,13]],"date-time":"2020-04-13T14:02:41Z","timestamp":1586786561000},"page":"1774-1779","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["The Chicago Consensus on Peritoneal Surface Malignancies: Management of Peritoneal Mesothelioma"],"prefix":"10.1245","volume":"27","author":[{"name":"Chicago Consensus Working Group","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,4,13]]},"reference":[{"key":"8324_CR1","doi-asserted-by":"publisher","unstructured":"Chicago Consensus Working Group. The Chicago Consensus Guidelines for Peritoneal Surface Malignancies: Introduction. Ann Surg Oncol. 2020. https:\/\/doi.org\/10.1245\/s10434-020-08318-8.","DOI":"10.1245\/s10434-020-08318-8"},{"key":"8324_CR2","doi-asserted-by":"publisher","unstructured":"Chicago Consensus Working Group. The Chicago Consensus on Peritoneal Surface Malignancies: Methodology. Ann Surg Oncol. 2020. https:\/\/doi.org\/10.1245\/s10434-020-08317-9.","DOI":"10.1245\/s10434-020-08317-9"},{"key":"8324_CR3","doi-asserted-by":"publisher","unstructured":"Chicago Consensus Working Group. The Chicago Consensus on Peritoneal Surface Malignancies: Standards. Ann Surg Oncol. 2020. https:\/\/doi.org\/10.1245\/s10434-020-08325-9.","DOI":"10.1245\/s10434-020-08325-9"},{"key":"8324_CR4","doi-asserted-by":"publisher","unstructured":"Chicago Consensus Working Group. The Chicago Consensus on Peritoneal Surface Malignancies: Management of Appendiceal Neoplasms. Ann Surg Oncol. 2020. https:\/\/doi.org\/10.1245\/s10434-020-08316-w.","DOI":"10.1245\/s10434-020-08316-w"},{"key":"8324_CR5","doi-asserted-by":"publisher","unstructured":"Chicago Consensus Working Group. The Chicago Consensus on Peritoneal Surface Malignancies: Management of Colorectal Metastases. Ann Surg Oncol. 2020. https:\/\/doi.org\/10.1245\/s10434-020-08315-x.","DOI":"10.1245\/s10434-020-08315-x"},{"key":"8324_CR6","doi-asserted-by":"publisher","unstructured":"Chicago Consensus Working Group. The Chicago Consensus on Peritoneal Surface Malignancies: Management of Gastric Metastases. Ann Surg Oncol. 2020. https:\/\/doi.org\/10.1245\/s10434-020-08320-0.","DOI":"10.1245\/s10434-020-08320-0"},{"key":"8324_CR7","doi-asserted-by":"publisher","unstructured":"Chicago Consensus Working Group. The Chicago Consensus on Peritoneal Surface Malignancies: Management of Ovarian Neoplasms. Ann Surg Oncol. 2020. https:\/\/doi.org\/10.1245\/s10434-020-08322-y.","DOI":"10.1245\/s10434-020-08322-y"},{"key":"8324_CR8","doi-asserted-by":"publisher","unstructured":"Chicago Consensus Working Group. The Chicago Consensus on Peritoneal Surface Malignancies: Management of Neuroendocrine Tumors. Ann Surg Oncol. 2020. https:\/\/doi.org\/10.1245\/s10434-020-08321-z.","DOI":"10.1245\/s10434-020-08321-z"},{"key":"8324_CR9","doi-asserted-by":"publisher","unstructured":"Chicago Consensus Working Group. The Chicago Consensus on Peritoneal Surface Malignancies: Management of Desmoplastic Small Round Cell Tumor, Breast, and Gastrointestinal Stromal Tumor. Ann Surg Oncol. 2020. https:\/\/doi.org\/10.1245\/s10434-020-08319-7.","DOI":"10.1245\/s10434-020-08319-7"},{"key":"8324_CR10","doi-asserted-by":"publisher","unstructured":"Chicago Consensus Working Group. The Chicago Consensus on Peritoneal Surface Malignancies: Palliative Care Considerations. Ann Surg Oncol. 2020. https:\/\/doi.org\/10.1245\/s10434-020-08323-x.","DOI":"10.1245\/s10434-020-08323-x"},{"issue":"1","key":"8324_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1179\/2049396712Y.0000000016","volume":"19","author":"SJ Henley","year":"2013","unstructured":"Henley SJ, Larson TC, Wu M, et al. Mesothelioma incidence in 50 states and the District of Columbia, United States, 2003-2008. Int J Occup Environ Health. 2013;19(1):1\u201310.","journal-title":"Int J Occup Environ Health"},{"issue":"28","key":"8324_CR12","doi-asserted-by":"publisher","first-page":"2863","DOI":"10.1200\/JCO.2018.78.5204","volume":"36","author":"V Panou","year":"2018","unstructured":"Panou V, Gadiraju M, Wolin A, et al. Frequency of germline mutations in cancer susceptibility genes in malignant mesothelioma. J Clin Oncol. 2018;36(28):2863\u20132871.","journal-title":"J Clin Oncol."},{"key":"8324_CR13","doi-asserted-by":"crossref","unstructured":"Husain AN, Colby T, Ordonez NG, et al; International Mesothelioma Interest Group. Guidelines for pathologic diagnosis of malignant mesothelioma: 2012 update of the consensus statement from the International Mesothelioma Interest Group. Arch Pathol Lab Med. 2013;137(5):647\u2013667.","DOI":"10.5858\/arpa.2012-0214-OA"},{"issue":"6","key":"8324_CR14","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/j.humpath.2003.11.013","volume":"35","author":"NG Ord\u00f3\u00f1ez","year":"2004","unstructured":"Ord\u00f3\u00f1ez NG. The diagnostic utility of immunohistochemistry in distinguishing between mesothelioma and renal cell carcinoma: a comparative study. Hum Pathol. 2004;35(6):697-710.","journal-title":"Hum Pathol"},{"key":"8324_CR15","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1186\/s12967-015-0485-1","volume":"13","author":"H Alakus","year":"2015","unstructured":"Alakus H, Yost SE, Woo B, et al. BAP1 mutation is a frequent somatic event in peritoneal malignant mesothelioma. J Transl Med. 2015;13:122.","journal-title":"J Transl Med"},{"issue":"36","key":"8324_CR16","doi-asserted-by":"publisher","first-page":"6237","DOI":"10.1200\/JCO.2009.23.9640","volume":"27","author":"TD Yan","year":"2009","unstructured":"Yan TD, Deraco M, Baratti D, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience. J Clin Oncol. 2009;27(36):6237\u20136242.","journal-title":"J Clin Oncol"},{"issue":"5","key":"8324_CR17","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1245\/s10434-012-2237-2","volume":"19","author":"D Baratti","year":"2012","unstructured":"Baratti D, Kusamura S, Cabras AD, Deraco M. Cytoreductive surgery with selective versus complete parietal peritonectomy followed by hyperthermic intraperitoneal chemotherapy in patients with diffuse malignant peritoneal mesothelioma: a controlled study. Ann Surg Oncol. 2012;19(5):1416\u20131424.","journal-title":"Ann Surg Oncol"},{"key":"8324_CR18","doi-asserted-by":"crossref","unstructured":"Kepenekian V, Elias D, Passot G, et al; French Network for Rare Peritoneal Malignancies (RENAPE). Diffuse malignant peritoneal mesothelioma: evaluation of systemic chemotherapy with comprehensive treatment through the RENAPE database: multi-institutional retrospective study. Eur J Cancer. 2016;65:69\u201379.","DOI":"10.1016\/j.ejca.2016.06.002"},{"issue":"5","key":"8324_CR19","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1245\/s10434-014-3977-y","volume":"22","author":"C Ihemelandu","year":"2015","unstructured":"Ihemelandu C, Bijelic L, Sugarbaker PH. Iterative cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent or progressive diffuse malignant peritoneal mesothelioma: clinicopathologic characteristics and survival outcome. Ann Surg Oncol. 2015;22(5):1680\u20131685.","journal-title":"Ann Surg Oncol"},{"issue":"8","key":"8324_CR20","doi-asserted-by":"publisher","first-page":"565","DOI":"10.3109\/02656736.2014.974693","volume":"30","author":"M Vaira","year":"2014","unstructured":"Vaira M, Robella M, Mellano A, Sottile A, De Simone M. Iterative procedures combining cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for isolated peritoneal recurrence. Int J Hyperthermia. 2014;30(8):565\u2013569.","journal-title":"Int J Hyperthermia"},{"issue":"5","key":"8324_CR21","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1245\/s10434-014-3978-x","volume":"22","author":"JH Helm","year":"2015","unstructured":"Helm JH, Miura JT, Glenn JA, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: a systematic review and meta-analysis. Ann Surg Oncol. 2015;22(5):1686\u20131693.","journal-title":"Ann Surg Oncol"},{"issue":"7","key":"8324_CR22","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1016\/j.ejso.2017.01.009","volume":"43","author":"PH Sugarbaker","year":"2017","unstructured":"Sugarbaker PH, Chang D. Long-term regional chemotherapy for patients with epithelial malignant peritoneal mesothelioma results in improved survival. Eur J Surg Oncol. 2017;43(7):1228\u20131235.","journal-title":"Eur J Surg Oncol."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-020-08324-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-020-08324-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-020-08324-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,12]],"date-time":"2021-04-12T23:05:31Z","timestamp":1618268731000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-020-08324-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,13]]},"references-count":22,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["8324"],"URL":"https:\/\/doi.org\/10.1245\/s10434-020-08324-w","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,13]]},"assertion":[{"value":"4 July 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2020","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Garrett M. Nash reports non-financial support from Intuitive outside the submitted work. James C. Cusack reports grants from Lumicell Inc. outside the submitted work. Carla Harmath serves on the medical advisory council of Accumen. Hedy Kindler reports personal fees and non-financial support from Inventiva, AstraZeneca, Boehringer Ingelheim, Merck, and Paredox; personal fees from Aldeyra Therapeutics, Bayer, BMS, Erytech, Five Prime Therapeutics, Ipsen Pharmaceuticals, Kyowa, and MedImmune; and funds to support clinical trials at her institution from Aduro, AstraZeneca, Bayer, BMS, Deciphera, GSK, Lilly, Merck, MedImmune, Polaris, Verastem, and Blueprint, all outside the submitted work. Aytekin Oto reports grants from Philips Healthcare, Guerbet, and Profound Healthcare, and serves as a medical advisory board member for Profound Healthcare, all outside the submitted work. Nita Ahuja reports grant funding from Cepheid and Astex, has served as a consultant to Ethicon, and has licensed methylation biomarkers to Cepheid. Jesus Esquivel reports personal fees from Eight Medical. The remaining authors disclosed no conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}